Literature DB >> 20473378

Fenofibrate Reduces Age-related Hypercholesterolemia in Normal Rats on a Standard Diet.

Ying Han1, Mi-Hyang Do, Mi Sun Kim, Eunhui Seo, Mi-Kyoung Park, Duk Kyu Kim, Hye-Jeong Lee, Su-Yeong Seo.   

Abstract

Plasma cholesterol is increased in normal aging in both rodents and humans. This is associated with reduced elimination of cholesterol and decreased receptor-mediated clearance of plasma low-density lipoprotein (LDL) cholesterol. The aims of this study were: (1) to determine age-related changes in plasma lipid profiles, and (2) to determine the effect of fenofibrate, an activator of peroxisome proliferator activated receptor alpha (PPAR alpha), on plasma lipid profiles in normal rats on a standard diet. Male Sprague-Dawley (SD) rats (n=15) were fed standard chow and water from 10 to 25 weeks of age. During that period, we measured daily food intake, body weight, fasting and random blood glucose levels, plasma total cholesterol (TC), triglycerides (TG), and free fatty acid (FFA) levels. At 20 weeks of age, all rats were randomly divided into two groups: a fenofibrate group (in which rats were gavaged with 300 mg/kg/day of fenofibrate) and a control group (gavaged with water). Fenofibrate treatment lasted 5 weeks. There were no significant changes in daily food intake, blood glucose, and plasma TG level with age. Body weight, plasma TC, and FFA levels were significantly increased with age. Fenofibrate significantly decreased plasma concentrations of TC and FFA, which had been increased with age. However, fenofibrate did not influence the plasma concentration of TG, which had not increased with age. These results suggest that fenofibrate might have a novel role in preventing age-related hypercholesterolemia in SD rats on a normal diet.

Entities:  

Keywords:  Aging; Fenofibrate; Hypercholesterolemia; PPAR α; Sprague-Dawley rats

Year:  2010        PMID: 20473378      PMCID: PMC2869456          DOI: 10.4196/kjpp.2010.14.2.77

Source DB:  PubMed          Journal:  Korean J Physiol Pharmacol        ISSN: 1226-4512            Impact factor:   2.016


  20 in total

Review 1.  Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.

Authors:  Harold Bays; Lawrence Mandarino; Ralph A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

2.  Drug treatment of dyslipidemias: practical guidelines for the primary care physician.

Authors:  H E Bays; C A Dujovne; A M Lansing
Journal:  Heart Dis Stroke       Date:  1992 Nov-Dec

3.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.

Authors:  I Issemann; S Green
Journal:  Nature       Date:  1990-10-18       Impact factor: 49.962

4.  Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries.

Authors:  Maria Alvarez de Sotomayor; Carmen Mingorance; Ramaroson Andriantsitohaina
Journal:  Atherosclerosis       Date:  2006-09-18       Impact factor: 5.162

Review 5.  Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program.

Authors:  S M Grundy; J I Cleeman; B M Rifkind; L H Kuller
Journal:  Arch Intern Med       Date:  1999 Aug 9-23

6.  Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.

Authors:  E Chaput; R Saladin; M Silvestre; A D Edgar
Journal:  Biochem Biophys Res Commun       Date:  2000-05-10       Impact factor: 3.575

7.  Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats.

Authors:  F P Mancini; A Lanni; L Sabatino; M Moreno; A Giannino; F Contaldo; V Colantuoni; F Goglia
Journal:  FEBS Lett       Date:  2001-02-23       Impact factor: 4.124

8.  Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.

Authors:  Longina Kłosiewicz-Latoszek; Wiktor B Szostak; Barbara Grzybowska; Janina Białobrzeska-Paluszkiewicz; Beata Wiśniewska; Irena Stolarska
Journal:  Kardiol Pol       Date:  2004-06       Impact factor: 3.108

9.  The influence of age on low density lipoprotein metabolism: effects of cholestyramine treatment in young and old healthy male subjects.

Authors:  S Ericsson; L Berglund; J Frostegård; K Einarsson; B Angelin
Journal:  J Intern Med       Date:  1997-10       Impact factor: 8.989

10.  Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats.

Authors:  Akio Kobayashi; Yusuke Suzuki; Hideyuki Kuno; Shoichiro Sugai; Hiroyuki Sakakibara; Kayoko Shimoi
Journal:  J Toxicol Sci       Date:  2009-10       Impact factor: 2.196

View more
  3 in total

Review 1.  Kidney aging--inevitable or preventable?

Authors:  Devasmita Choudhury; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

2.  Reduction of Food Intake by Fenofibrate is Associated with Cholecystokinin Release in Long-Evans Tokushima Rats.

Authors:  Mi-Kyoung Park; Ying Han; Mi Sun Kim; Eunhui Seo; Soojeong Kang; So-Young Park; Hyeongjong Koh; Duk Kyu Kim; Hye-Jeong Lee
Journal:  Korean J Physiol Pharmacol       Date:  2012-06-26       Impact factor: 2.016

3.  Ovariectomy Impaired Hepatic Glucose and Lipid Homeostasis and Altered the Gut Microbiota in Mice With Different Diets.

Authors:  Zili Lei; Huijuan Wu; Yanhong Yang; Qing Hu; Yuting Lei; Wanwan Liu; Ya Nie; Lanxiang Yang; Xueying Zhang; Changyuan Yang; Ting Lin; Fengxue Tong; Jiamin Zhu; Jiao Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-30       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.